# Validation of Digital-PCR Analysis Through Programmed Imatinib Interruption in PCR Negative CML Patients

> **NCT01578213** · PHASE4 · COMPLETED · sponsor: **University of Milano Bicocca** · enrollment: 112 (actual)

## Conditions studied

- Chronic Myeloid Leukemia

## Interventions

- **DRUG:** Imatinib mesylate

## Key facts

- **NCT ID:** NCT01578213
- **Lead sponsor:** University of Milano Bicocca
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11-09
- **Primary completion:** 2018-11-28
- **Final completion:** 2018-11-28
- **Target enrollment:** 112 (ACTUAL)
- **Last updated:** 2019-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01578213

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01578213, "Validation of Digital-PCR Analysis Through Programmed Imatinib Interruption in PCR Negative CML Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01578213. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*